Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma announced positive top-line results from two Phase 3 clinical trials (INSPIRE-1 and INSPIRE-2) evaluating Tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA). Both studies met their primary endpoint, showing statistically significant improvements in ACR20 response rates at Week 24 compared to placebo. The trials together enrolled over 800 patients across the US, Europe, and Asia, with INSPIRE-1 covering anti-TNF experienced patients and INSPIRE-2 covering anti-TNF naïve patients. No new safety signals were identified, and the safety profile was consistent with ILUMYA's existing label for plaque psoriasis. These results will support a potential regulatory submission in the US to expand ILUMYA's indication to include psoriatic arthritis.
This is a positive development for Sun Pharma, as successful Phase 3 results pave the way for a potential label expansion of ILUMYA into the psoriatic arthritis market, opening up a sizeable new revenue opportunity in the US specialty portfolio. Shareholders may view this as a positive growth catalyst, though actual revenue impact depends on USFDA approval and successful launch.